This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sanati, H.
Right arrow Articles by Ghannoum, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sanati, H.
Right arrow Articles by Ghannoum, M. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, Jun 1997, 1345-1348, Vol 41, No. 6
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

Combination therapy with amphotericin B and fluconazole against invasive candidiasis in neutropenic-mouse and infective-endocarditis rabbit models

H Sanati, CF Ramos, AS Bayer and MA Ghannoum
Department of Internal Medicine, Harbor-UCLA Medical Center, Torrance, California 90509, USA.

Although there are an increasing number of new antifungal agents available, the morbidity and mortality due to invasive mycoses remain high. The high rates of polyene toxicities and the development of azole resistance have raised the issue of using antifungal agents of these classes in combination, despite theoretical concerns regarding antagonism between such agents. This study was designed to evaluate the in vivo efficacy of combined therapy with amphotericin B and fluconazole against Candida albicans. Two distinct animal models were used in this study: a neutropenic-mouse model of hematogenously disseminated candidiasis and the infective-endocarditis rabbit model. Treatment efficacy was assessed by determining reductions in mortality as well as decreases in tissue fungal densities. In the neutropenic- mouse model, amphotericin B, as well as combination therapy, significantly prolonged survival compared to untreated controls (P < 10(-5) and P = 0.001, respectively). The fungal densities in the kidneys of neutropenic mice were significantly reduced with either amphotericin B monotherapy or amphotericin B-fluconazole combined therapy compared to those of controls (P < 10(-6)). Fluconazole monotherapy also reduced fungal densities in the kidneys; however, this decrease was not statistically significant (P = 0.17). In contrast, treatment with either fluconazole alone or combined with amphotericin B (but not amphotericin B monotherapy) significantly decreased fungal densities in the brain (P = 0.025). In the rabbit endocarditis model, amphotericin B monotherapy or combined therapy significantly decreased fungal densities in cardiac vegetations (P < 0.01 versus the controls). Although no significant antagonism was seen when fluconazole was given in combination with amphotericin B, combination therapy did not augment the antifungal activity of amphotericin B.


This article has been cited by other articles:

  • Cacciapuoti, A., Gurnani, M., Halpern, J., Norris, C., Patel, R., Loebenberg, D. (2005). Interaction between Posaconazole and Amphotericin B in Concomitant Treatment against Candida albicans In Vivo. Antimicrob. Agents Chemother. 49: 638-642 [Abstract] [Full Text]  
  • Mukherjee, P. K., Sheehan, D. J., Hitchcock, C. A., Ghannoum, M. A. (2005). Combination Treatment of Invasive Fungal Infections. Clin. Microbiol. Rev. 18: 163-194 [Abstract] [Full Text]  
  • Cuenca-Estrella, M. (2004). Combinations of antifungal agents in therapy-what value are they?. J Antimicrob Chemother 54: 854-869 [Abstract] [Full Text]  
  • Barchiesi, F., Spreghini, E., Schimizzi, A. M., Maracci, M., Giannini, D., Carle, F., Scalise, G. (2004). Posaconazole and Amphotericin B Combination Therapy against Cryptococcus neoformans Infection. Antimicrob. Agents Chemother. 48: 3312-3316 [Abstract] [Full Text]  
  • Barchiesi, F., Spreghini, E., Maracci, M., Fothergill, A. W., Baldassarri, I., Rinaldi, M. G., Scalise, G. (2004). In Vitro Activities of Voriconazole in Combination with Three Other Antifungal Agents against Candida glabrata. Antimicrob. Agents Chemother. 48: 3317-3322 [Abstract] [Full Text]  
  • Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., Rex, J. H. (2004). Combination Antifungal Therapy. Antimicrob. Agents Chemother. 48: 693-715 [Full Text]  
  • Matthews, R. C., Rigg, G., Hodgetts, S., Carter, T., Chapman, C., Gregory, C., Illidge, C., Burnie, J. (2003). Preclinical Assessment of the Efficacy of Mycograb, a Human Recombinant Antibody against Fungal HSP90. Antimicrob. Agents Chemother. 47: 2208-2216 [Abstract] [Full Text]  
  • Manavathu, E. K., Alangaden, G. J., Chandrasekar, P. H. (2003). Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus. J Antimicrob Chemother 51: 1423-1425 [Abstract] [Full Text]  
  • Kirkpatrick, W. R., Perea, S., Coco, B. J., Patterson, T. F. (2002). Efficacy of Caspofungin Alone and in Combination with Voriconazole in a Guinea Pig Model of Invasive Aspergillosis. Antimicrob. Agents Chemother. 46: 2564-2568 [Abstract] [Full Text]  
  • Wang, Z., Zheng, L., Liu, H., Wang, Q., Hauser, M., Kauffman, S., Becker, J. M., Szaniszlo, P. J. (2001). WdChs2p, a Class I Chitin Synthase, Together with WdChs3p (Class III) Contributes to Virulence in Wangiella (Exophiala) dermatitidis. Infect. Immun. 69: 7517-7526 [Abstract] [Full Text]  
  • Barchiesi, F., Schimizzi, A. M., Najvar, L. K., Bocanegra, R., Caselli, F., Di Cesare, S., Giannini, D., Di Francesco, L. F., Giacometti, A., Carle, F., Scalise, G., Graybill, J. R. (2001). Interactions of Posaconazole and Flucytosine against Cryptococcus neoformans. Antimicrob. Agents Chemother. 45: 1355-1359 [Abstract] [Full Text]  
  • Louie, A., Kaw, P., Banerjee, P., Liu, W., Chen, G., Miller, M. H. (2001). Impact of the Order of Initiation of Fluconazole and Amphotericin B in Sequential or Combination Therapy on Killing of Candida albicans In Vitro and in a Rabbit Model of Endocarditis and Pyelonephritis. Antimicrob. Agents Chemother. 45: 485-494 [Abstract] [Full Text]  
  • Marchetti, O., Entenza, J. M., Sanglard, D., Bille, J., Glauser, M. P., Moreillon, P. (2000). Fluconazole plus Cyclosporine: a Fungicidal Combination Effective against Experimental Endocarditis Due to Candida albicans. Antimicrob. Agents Chemother. 44: 2932-2938 [Abstract] [Full Text]  
  • Barchiesi, F., Schimizzi, A. M., Caselli, F., Novelli, A., Fallani, S., Giannini, D., Arzeni, D., Di Cesare, S., Di Francesco, L. F., Fortuna, M., Giacometti, A., Carle, F., Mazzei, T., Scalise, G. (2000). Interactions between Triazoles and Amphotericin B against Cryptococcus neoformans. Antimicrob. Agents Chemother. 44: 2435-2441 [Abstract] [Full Text]  
  • Louie, A., Liu, W., Miller, D. A., Sucke, A. C., Liu, Q.-F., Drusano, G. L., Mayers, M., Miller, M. H. (1999). Efficacies of High-Dose Fluconazole plus Amphotericin B and High-Dose Fluconazole plus 5-Fluorocytosine versus Amphotericin B, Fluconazole, and 5-Fluorocytosine Monotherapies in Treatment of Experimental Endocarditis, Endophthalmitis, and Pyelonephritis Due to Candida albicans. Antimicrob. Agents Chemother. 43: 2831-2840 [Abstract] [Full Text]  
  • Louie, A., Banerjee, P., Drusano, G. L., Shayegani, M., Miller, M. H. (1999). Interaction between Fluconazole and Amphotericin B in Mice with Systemic Infection Due to Fluconazole-Susceptible or -Resistant Strains of Candida albicans. Antimicrob. Agents Chemother. 43: 2841-2847 [Abstract] [Full Text]  
  • Sheehan, D. J., Hitchcock, C. A., Sibley, C. M. (1999). Current and Emerging Azole Antifungal Agents. Clin. Microbiol. Rev. 12: 40-79 [Abstract] [Full Text]  
  • White, T. C., Marr, K. A., Bowden, R. A. (1998). Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance. Clin. Microbiol. Rev. 11: 382-402 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»